

L Number	Hits	Search Text	DB	Time stamp
1	195	("562/453").CCLS.	USPAT; EPO; JPO; DERWENT	2001/07/19 12:19
2	421	("562/432").CCLS.	USPAT; EPO; JPO; DERWENT	2001/07/19 12:19
3	669	("560/12").CCLS.	USPAT; EPO; JPO; DERWENT	2001/07/19 12:19
4	373	("560/42").CCLS.	USPAT; EPO; JPO; DERWENT	2001/07/19 12:19
5	2341	NMDA	USPAT; EPO; JPO; DERWENT	2001/07/19 12:20
6	8707	Aspirin	USPAT; EPO; JPO; DERWENT	2001/07/19 12:20
7	89	NMDA and Aspirin	USPAT; EPO; JPO; DERWENT	2001/07/19 12:20
8	49832	neuro\$	USPAT; EPO; JPO; DERWENT	2001/07/19 12:21
9	81	(NMDA and Aspirin) and neuro\$	USPAT; EPO; JPO; DERWENT	2001/07/19 12:21
10	2096	aminosalicylic	USPAT; EPO; JPO; DERWENT	2001/07/19 12:22
11	1	((NMDA and Aspirin) and neuro\$) and aminosalicylic	USPAT; EPO; JPO; DERWENT	2001/07/19 12:23
12	21	NMDA and aminosalicylic	USPAT; EPO; JPO; DERWENT	2001/07/19 12:28
13	0	neurodegenat\$	USPAT; EPO; JPO; DERWENT	2001/07/19 12:28
14	6557	neurodegenerat\$	USPAT; EPO; JPO; DERWENT	2001/07/19 12:28
15	23	aminosalicylic and neurodegenerat\$	USPAT; EPO; JPO; DERWENT	2001/07/19 12:36
16	1543	((("562/453").CCLS.) or (("562/432").CCLS.) or or (("560/12").CCLS.) or (("560/42").CCLS.)	USPAT; EPO; JPO; DERWENT	2001/07/19 12:37
17	21	neurodegenerat\$ and (((("562/453").CCLS.) or (("562/432").CCLS.) or (("560/12").CCLS.) or (("560/42").CCLS.))	USPAT; EPO; JPO; DERWENT	2001/07/19 12:42
18	108	excitory	USPAT; EPO; JPO; DERWENT	2001/07/19 12:43
19	2847	excitatory	USPAT; EPO; JPO; DERWENT	2001/07/19 12:43
20	53816	antagonist\$	USPAT; EPO; JPO; DERWENT	2001/07/19 12:43
21	1669	excitatory and antagonist\$	USPAT; EPO; JPO; DERWENT	2001/07/19 12:44
22	11	aminosalicylic and (excitatory and antagonist\$)	USPAT; EPO; JPO; DERWENT	2001/07/19 12:55
23	17	Paraaminosalicylic	USPAT; EPO; JPO; DERWENT	2001/07/19 12:55

	Type	L #	Hits	Search Text	DBs	Time Stamp
1	IS&R	L1	195	("562/453").CCLS.	USPAT; EPO; JPO; DERWENT	2001/07/19 12:19
2	IS&R	L2	421	("562/432").CCLS.	USPAT; EPO; JPO; DERWENT	2001/07/19 12:19
3	IS&R	L3	669	("560/12").CCLS.	USPAT; EPO; JPO; DERWENT	2001/07/19 12:19
4	IS&R	L4	373	("560/42").CCLS.	USPAT; EPO; JPO; DERWENT	2001/07/19 12:19
5	BRS	L5	2341	NMDA	USPAT; EPO; JPO; DERWENT	2001/07/19 12:20
6	BRS	L6	8707	Aspirin	USPAT; EPO; JPO; DERWENT	2001/07/19 12:20
7	BRS	L7	89	15 and 16	USPAT; EPO; JPO; DERWENT	2001/07/19 12:20
8	BRS	L8	49832	neuro\$	USPAT; EPO; JPO; DERWENT	2001/07/19 12:21
9	BRS	L9	81	17 and 18	USPAT; EPO; JPO; DERWENT	2001/07/19 12:21
10	BRS	L10	2096	aminosalicylic	USPAT; EPO; JPO; DERWENT	2001/07/19 12:22
11	BRS	L11	1	19 and 110	USPAT; EPO; JPO; DERWENT	2001/07/19 12:23
12	BRS	L12	21	15 and 110	USPAT; EPO; JPO; DERWENT	2001/07/19 12:28
13	BRS	L13	0	neurodegenat\$	USPAT; EPO; JPO; DERWENT	2001/07/19 12:28
14	BRS	L14	6557	neurodegenerat\$	USPAT; EPO; JPO; DERWENT	2001/07/19 12:28
15	BRS	L15	23	110 and 114	USPAT; EPO; JPO; DERWENT	2001/07/19 12:36

	Comments	Error Definition	Errors
1			0
2			0
3			0
4			0
5			0
6			0
7			0
8		Truncation Overflow. Return string from Server is: 5`0`0`NEU	1
9			0
10			0
11			0
12			0
13			0
14			0
15			0

	Type	L #	Hits	Search Text	DBs	Time Stamp
16	BRS	L16	1543	11 or 12 or 13 or 14	USPAT; EPO; JPO; DERWENT	2001/07/19 12:37
17	BRS	L17	21	114 and 116	USPAT; EPO; JPO; DERWENT	2001/07/19 12:42
18	BRS	L18	108	excitory	USPAT; EPO; JPO; DERWENT	2001/07/19 12:43
19	BRS	L19	2847	excitatory	USPAT; EPO; JPO; DERWENT	2001/07/19 12:43
20	BRS	L20	53816	antagonist\$	USPAT; EPO; JPO; DERWENT	2001/07/19 12:43
21	BRS	L21	1669	119 and 120	USPAT; EPO; JPO; DERWENT	2001/07/19 12:44
22	BRS	L22	11	110 and 121	USPAT; EPO; JPO; DERWENT	2001/07/19 12:55
23	BRS	L23	17	Paraaminosalicylic	USPAT; EPO; JPO; DERWENT	2001/07/19 12:55

	Comments	Error Definition	Errors
16			0
17			0
18			0
19			0
20			0
21			0
22			0
23			0

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal623paz

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files  
NEWS 3 Feb 06 Engineering Information Encompass files have new names  
NEWS 4 Feb 16 TOXLINE no longer being updated  
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure  
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA  
NEWS 7 May 07 DGENE Reload  
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL  
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's  
DWPI and DPCI

NEWS EXPRESS July 11 CURRENT WINDOWS VERSION IS V6.0b,  
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 13:02:17 ON 19 JUL 2001

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.15

0.15

FILE 'REGISTRY' ENTERED AT 13:02:44 ON 19 JUL 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 18 JUL 2001 HIGHEST RN 346684-23-9  
DICTIONARY FILE UPDATES: 18 JUL 2001 HIGHEST RN 346684-23-9

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT  
for details.

=>


Uploading 09557001 bas exact.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> search

ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):l1

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:exact

ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full

FULL SEARCH INITIATED 13:03:26 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3 TO ITERATE

100.0% PROCESSED 3 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.02

L2 0 SEA EXA FUL L1

=> search

ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):l1

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss

ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full

FULL SEARCH INITIATED 13:04:44 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 539 TO ITERATE

100.0% PROCESSED 539 ITERATIONS

149 ANSWERS

SEARCH TIME: 00.00.01

L3 149 SEA SSS FUL L1

=> dscan

0 DSCAN

L4

0 DSCAN

=> d scan

L4 HAS NO ANSWERS

=> d scan 12


L2 HAS NO ANSWERS

=> d scan 13

L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS

IN Benzoic acid, 3,3'-[1,3-phenylenebis(carbonylimino)]bis[6-hydroxy- (9CI)

MF C22 H16 N2 O8



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):40

L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS

IN Ferrate(7-),

bis[5-[[4-[[5-[[3-carboxy-4-hydroxyphenyl]amino]carbonyl]-2-



(hydroxy-.kappa.O)phenyl]azo-.kappa.N1]-3-(hydroxy-.kappa.O)-1-

naphthalenyl]azo]-1,3-benzenedicarboxylato(5-)]-, heptahydrogen (9CI)

MF C64 H32 Fe N10 O20 . 7 H

CI CCS







● 7 H<sup>+</sup>

L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid,  
 5-[p-[1-hydroxy-6-[3-[5-hydroxy-7-sulfo-6-(3,6,8-trisulfo-  
 1-naphthylazo)-2-naphthyl]ureido]-3-sulfo-2-naphthylazo]benzamido]- (6CI)  
 MF C45 H31 N7 O22 S5

PAGE 1-A







PAGE 1-B





L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5,5'-[ureylenebis[p-phenyleneimino(1-hydroxy-3-sulfo-6,2-naphthylene)azo[3-(carboxymethoxy)-4,1-naphthylene]azo-m-phenylenecarbonylimino]]di- (6CI)  
 MF C85 H60 N14 O23 S2

PAGE 1-A




PAGE 1-B







L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-(5-amino-2-chlorobenzamido)- (6CI)  
 MF C14 H11 Cl N2 O4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[1-hydroxy-6-[3-[5-hydroxy-7-sulfo-6-(p-sulfophenylazo)-2-naphthyl]ureido]-3-sulfo-2-naphthylazo]benzamido]-  
 (6CI)  
 MF C41 H29 N7 O16 S3




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(4-fluorobenzoyl)amino]-2-hydroxy-, compd. with  
 1H-imidazole (1:1) (9CI)  
 MF C14 H10 F N O4 . C3 H4 N2


CM 1



CM 2




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(2,6-difluorobenzoyl)amino]-2-hydroxy- (9CI)  
 MF C14 H9 F2 N O4  
 CI COM




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[6-[3-[6-(4-ethoxy-2-sulfophenylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-  
 (6CI)  
 MF C43 H33 N7 O17 S3


PAGE 1-A




PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 3,3',3''-[1,3,5-benzenetriyltris(carbonylimino)]tris[6-  
 hydroxy- (9CI)  
 MF C30 H21 N3 O12




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(2,4-dihydroxybenzoyl)amino]-2-hydroxy- (9CI)  
 MF C14 H11 N O6  
 CI COM



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(4-fluorobenzoyl)amino]-2-hydroxy- (9CI)  
 MF C14 H10 F N O4  
 CI COM




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[(8-acetamido-1-hydroxy-3,5-disulfo-2-naphthyl)azo]benzamido]-3-sulfo-, tetrasodium salt (8CI)  
 MF C26 H20 N4 O15 S3 . 4 Na




● 4 Na


L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[[4-[(1-oxodecyl)amino]benzoyl]amino]- (9CI)  
 MF C24 H30 N2 O5



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid,  
 2-hydroxy-5-[[phenyl[(phenylsulfonyl)amino]methylene]amino]-  
 (9CI)  
 MF C20 H16 N2 O5 S



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 hydrochloride (9CI)  
 MF C14 H13 N O5 . Cl H




● HCl


L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[1-hydroxy-6-[3-[5-hydroxy-7-sulfo-6-(1-sulfo-2-naphthylazo)-2-naphthyl]ureido]-3-sulfo-2-naphthylazo]benzamido]- (6CI)  
 MF C45 H31 N7 O16 S3





PAGE 1-A



PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Salicylic acid,  
5-[p-[3-(carboxymethoxy)-4-[6-[p-[4,6-dianilino-s-triazin-  
2-yl)amino]anilino]-1-hydroxy-3-sulfo-2-naphthylazo]-7-sulfo-1-  
naphthylazo]benzamido]- (6CI)  
MF C57 H42 N12 O14 S2




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[6-[3-[6-(5,7-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-(6CI)  
 MF C45 H31 N7 O19 S4


PAGE 1-A



PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Salicylic acid, 5-(m-aminobenzamido)-3-chloro- (6CI)  
MF C14 H11 Cl N2 O4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Benzoic acid, 5-[[[2',4'-difluoro-3-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]amino]-2-hydroxy-, compd. with 1H-imidazole (1:1) (9CI)  
MF C20 H13 F2 N O5 . C3 H4 N2


CM 1




CM 2



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(2,4-dichlorobenzoyl)amino]-2-hydroxy- (9CI)  
 MF C14 H9 Cl2 N O4  
 CI COM




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[(3,4,5-trimethoxybenzoyl)amino]- (9CI)  
 MF C17 H17 N O7



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Strychnidin-10-one, 2,3-dimethoxy-, (-)-5-[(cyanophenylmethyl)amino]-2-hydroxybenzoate (9CI)  
 MF C23 H26 N2 O4 . x C15 H12 N2 O3


CM 1

Rotation (-).




CM 2


Absolute stereochemistry.



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Benzoic acid, 3-bromo-2-hydroxy-5-[(2-hydroxybenzoyl)amino]- (9CI)  
MF C14 H10 Br N O5  
CI COM




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Benzoic acid, 5-[[4-[[6-[(4-aminobenzoyl)amino]-1-hydroxy-3-sulfo-2-naphthalenyl]azo]benzoyl]amino]-2-hydroxy-, disodium salt (9CI)  
MF C31 H23 N5 O9 S . 2 Na




● 2 Na


L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(4-aminobenzoyl)amino]-2-hydroxy- (9CI)  
 MF C14 H12 N2 O4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[4-[(2-bromobenzoyl)amino]benzoyl]amino]-2-hydroxy- (9CI)  
 MF C21 H15 Br N2 O5



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[(2,3-dihydroxyphenyl)methyl]amino]-2-hydroxy- (9CI)  
 MF C14 H13 N O5




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy- (9CI)  
 MF C14 H13 N O5  
 CI COM




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN 2,3-Cresotic acid, 5-[p-[4-[6-[p-[3-[p-[[6-[4-[p-[(3-carboxy-4-hydroxyphenyl) carbamoyl]phenylazo]-2-(carboxymethoxy)-1-naphthylazo]-5-hydroxy-7-sulfo-2-naphthyl]amino]phenyl]ureido]anilino]-1-hydroxy-3-sulfo-2-naphthylazo]-3-(carboxymethoxy)-6-sulfo-1-naphthylazo]benzamido]- (6CI)  
 MF C86 H62 N14 O26 S3

PAGE 1-A




PAGE 1-B







PAGE 2-A



PAGE 2-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-(3-amino-4-chlorobenzamido)- (6CI)  
 MF C14 H11 Cl N2 O4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[2-chloro-5-[6-[3-[6-(6,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]- (6CI)  
 MF C45 H30 Cl N7 O19 S4

PAGE 1-A





PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN 2,3-Cresotic acid, 5-[p-[6-[3-[6-(6,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-  
 (6CI)  
 MF C46 H33 N7 O19 S4

PAGE 1-A







L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(3,5-difluorobenzoyl)amino]-2-hydroxy- (9CI)  
 MF C14 H9 F2 N O4  
 CI COM




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[1-hydroxy-6-[3-[5-hydroxy-6-(4-phenoxy-2-sulfo-phenylazo)-7-sulfo-2-naphthyl]ureido]-3-sulfo-2-naphthylazo]benzamido]- (6CI)  
 MF C47 H33 N7 O17 S3






L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 3,3',3''-[1,3,5-benzenetriyltris(carbonylimino)]tris[6-  
 hydroxy-5-methyl- (9CI)  
 MF C33 H27 N3 O12




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(2,4-dihydroxybenzoyl)amino]-2-hydroxy-, sodium salt  
 (9CI)  
 MF C14 H11 N O6 . x Na




●x Na

L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[(p-fluorobenzyl)amino]- (8CI)  
 MF C14 H12 F N O3




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[3-[[8-(acetylamino)-1-hydroxy-3,5-disulfo-2-naphthalenyl]azo]benzoyl]amino]-2-hydroxy-, trisodium salt (9CI)  
 MF C26 H20 N4 O12 S2 . 3 Na




●3 Na

L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[[4-[(1-oxooctyl)amino]benzoyl]amino]- (9CI)  
 MF C22 H26 N2 O5




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):100

L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid,  
 2-hydroxy-5-[[[4-(6-methylphenyl)sulfonyl]amino]phenylmethyle  
 ne]amino]- (9CI)  
 MF C21 H18 N2 O5 S




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[2,5-dimethoxyphenyl)methyl]amino]-2-hydroxy- (9CI)  
 MF C16 H17 N O5




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 3-chloro-5-[4-[6-[3-[6-(6,8-disulfo-2-naphthylazo)-5-  
 hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]-m-  
 toluamido]- (6CI)  
 MF C46 H32 Cl N7 O19 S4

PAGE 1-A





PAGE 1-B





L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[3-[6-[3-[6-(6,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]-p-toluidido]-(6CI)  
 MF C46 H33 N7 O19 S4

PAGE 1-A






L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[6-[3-[6-(6,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-3-sulfo- (6CI)  
 MF C45 H31 N7 O22 S5




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-(5-amino-2-chlorobenzamido)-3-sulfo- (6CI)  
 MF C14 H11 Cl N2 O7 S






L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[(4-methoxybenzoyl)amino]-, compd. with  
 1H-imidazole (1:1) (9CI)  
 MF C15 H13 N O5 . C3 H4 N2


CM 1




CM 2




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[(2-hydroxybenzoyl)amino]- (9CI)  
 MF C14 H11 N O5  
 CI COM




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN 2,3-Cresotic acid, 5-(5-amino-2,4-dichlorobenzamido)- (6CI)  
 MF C15 H12 Cl2 N2 O4



L3 149 ANSWERS . REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 3,3'-[(5-nitro-1,3-phenylene)bis(carbonylimino)]bis[6-hydroxy- (9CI)  
 MF C22 H15 N3 O10




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 3-bromo-2-hydroxy-5-[(2-hydroxybenzoyl)amino]-, monosodium salt (9CI)  
 MF C14 H10 Br N O5 . Na




● Na

L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[3-[[8-(acetylamino)-1-hydroxy-3,6-disulfo-2-naphthalenyl]azo]benzoyl]amino]-2-hydroxy-3-sulfo-, tetrasodium salt (9CI)  
 MF C26 H20 N4 O15 S3 . 4 Na




●4 Na


L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(3-aminobenzoyl)amino]-2-hydroxy-3-sulfo- (9CI)  
 MF C14 H12 N2 O7 S




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[(4-methylbenzoyl)amino]- (9CI)  
 MF C15 H13 N O4



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[ (2,4-dihydroxyphenyl)methyl]amino]-2-hydroxy- (9CI)  
 MF C14 H13 N O5




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid,  
 5-[[ (1,3-dihydro-1,3-dioxo-5-isobenzofuranyl) carbonyl]amino]-  
 2-hydroxy- (9CI)  
 MF C16 H9 N O7




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[4-[6-[3-[6-(4,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]-m-toluamido]-  
 (6CI)  
 MF C46 H33 N7 O19 S4

PAGE 1-A




PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN 2,3-Cresotic acid, 5-[4-[6-[3-[6-(4,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]-m-toluamido]-(6CI)  
 MF C47 H35 N7 O19 S4

PAGE 1-A




PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[4-chloro-3-[6-[3-[6-(6,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-(6CI)  
 MF C45 H30 Cl N7 O19 S4

PAGE 1-A





PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN 2,3-Cresotic acid, 5-[p-[6-[3-[6-(4,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-  
 (6CI)  
 MF C46 H33 N7 O19 S4

PAGE 1-A







L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[1,1'-biphenyl]-4-ylcarbonyl]amino]-2-hydroxy- (9CI)  
 MF C20 H15 N O4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid,  
 5-[p-[6-[3-[6-(2,4-dichloro-6-sulfophenylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-  
 (6CI)  
 MF C41 H27 Cl2 N7 O16 S3






L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN 1,3-Benzenedicarboxylic acid, 5,5',5'''-[1,3,5-  
 benzenetriyltris(carbonylimino)]tris[2-hydroxy- (9CI)  
 MF C33 H21 N3 O18




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(cyanophenylmethyl)amino]-2-hydroxy- (9CI)  
 MF C15 H12 N2 O3






L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN 2,4-Cresotic acid,  
 .alpha.,.alpha.,.alpha.-trifluoro-5-(p-fluorobenzamido)-  
 (8CI)  
 MF C15 H9 F4 N O4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[3-[(4-amino-9,10-dihydro-9,10-dioxo-3-sulfo-1-anthracenyl)amino]benzoyl]amino]-2-hydroxy-, monosodium salt (9CI)  
 MF C28 H19 N3 O9 S . Na




● Na


L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(2-bromobenzoyl)amino]-2-hydroxy- (9CI)  
 MF C14 H10 Br N O4



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid,  
 5-[[[4-chlorophenyl][[(4-methylphenyl)sulfonyl]amino]methyl-  
 ne]amino]-2-hydroxy- (9CI)  
 MF C21 H17 Cl N2 O5 S




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[5-(4-amino-1,4-dioxobutoxy)-2-  
 hydroxyphenyl]methyl]amino]-2-hydroxy- (9CI)  
 MF C18 H18 N2 O7




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5,5'-[(6-anilino-s-triazine-2,4-diyl)bis[imino-p-  
 phenyleneimino(1-hydroxy-3-sulfo-6,2-naphthylene)azo[3-(carboxymethoxy)-7-  
 sulfo-4,1-naphthylene]azo(3-methyl-p-phenylene)carbonylimino]]di- (6CI)  
 MF C95 H70 N18 O28 S4


PAGE 1-A




PAGE 1-B



PAGE 2-A




PAGE 2-B





L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid,  
 5,5'-[azobis[(1,5-dihydroxy-3-sulfo-6,2-naphthylene)azo-p-  
 phenylenecarbonylimino]]di-, copper deriv. (6CI)  
 MF C48 H26 Cu N8 O18 S2 . 4 H  
 CI CCS

PAGE 1-A





PAGE 1-B






L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[m-[6-[3-[6-(4,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-(6CI)  
 MF C45 H31 N7 O19 S4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[6-[3-[6-(2,4-disulfophenylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-(6CI)  
 MF C41 H29 N7 O19 S4

PAGE 1-A




PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[4-(heptyloxy)benzoyl]amino]-2-hydroxy-, compd. with  
 1H-imidazole (1:1) (9CI)  
 MF C21 H25 N O5 . C3 H4 N2

CM 1




CM 2




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[2',4'-difluoro-3-hydroxy[1,1'-biphenyl]-4-yl]carbonyl]amino]-2-hydroxy- (9CI)  
 MF C20 H13 F2 N O5


CI COM



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Salicylic acid, 5-[p-(1-amino-8-hydroxy-3,6-disulfo-2-naphthylazo)benzamido]- (6CI)  
MF C24 H18 N4 O11 S2



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Benzoic acid, 3,3'-[(5-nitro-1,3-phenylene)bis(carbonylimino)]bis[6-hydroxy-5-sulfo-, disodium salt (9CI)  
MF C22 H15 N3 O16 S2 . 2 Na




● 2 Na


L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Benzoic acid, 3-chloro-2-hydroxy-5-[(2-hydroxybenzoyl)amino]- (9CI)



MF C14 H10 Cl N O5




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Benzoic acid, 5-[[3-[[8-(acetylamino)-1-hydroxy-3,5-disulfo-2-naphthalenyl]azo]benzoyl]amino]-2-hydroxy-3-sulfo-, tetrasodium salt (9CI)  
MF C26 H20 N4 O15 S3 . 4 Na




● 4 Na


L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Benzoic acid, 5-[(3-amino-4-methylbenzoyl)amino]-2-hydroxy- (9CI)  
MF C15 H14 N2 O4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Benzoic acid, 2-hydroxy-5-[[3-[(3-methylbenzoyl)amino]benzoyl]amino]- (9CI)  
MF C22 H18 N2 O5




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[4-(diethylamino)-2-hydroxyphenyl]methyl]amino]-2-hydroxy- (9CI)  
 MF C18 H22 N2 O4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[[[4-(diethylamino)-2-hydroxyphenyl]methyl]amino]- (9CI)  
 MF C14 H13 N O4





L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[1-hydroxy-6-[3-[5-hydroxy-7-sulfo-6-(7-sulfo-2-naphthylazo)-2-naphthyl]ureido]-3-sulfo-2-naphthylazo]benzamido]- (6CI)  
 MF C45 H31 N7 O16 S3






L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN 2,3-Cresotic acid, 5-[4-[6-[3-[6-(6,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]-m-toluidamido]-  
 (6CI)  
 MF C47 H35 N7 O19 S4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[m-[6-[3-[6-(6,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-  
 (6CI)

MF C45 H31 N7 O19 S4

PAGE 1-A





PAGE 1-B



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN 2,3-Cresotic acid,  
5-[2,4-dichloro-5-[6-[3-[6-(6,8-disulfo-2-naphthylazo)-  
5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-  
naphthylazo]benzamido]- (6CI)  
MF C46 H31 Cl2 N7 O19 S4


PAGE 1-A






L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(2,4-dichlorobenzoyl)amino]-2-hydroxy-, compd. with  
 1H-imidazole (1:1) (9CI)  
 MF C14 H9 Cl2 N O4 . C3 H4 N2

CM 1




CM 2




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[6-[3-[6-(4-chloro-3-sulfo-phenylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-  
 (6CI)  
 MF C41 H28 Cl N7 O16 S3


PAGE 1-A



PAGE 1-B



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 3,3',3''-[1,3,5-benzenetriyltris(carbonylimino)]tris[6-  
 hydroxy-5-sulfo-, trisodium salt (9CI)  
 MF C30 H21 N3 O21 S3 . 3 Na




● 3 Na


L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS

IN Benzoic acid, 5-[(cyanophenylmethyl)amino]-2-hydroxy-, (+)- (9CI)  
MF C15 H12 N2 O3  
CI COM


Rotation (+).



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Salicylic acid, 5-[p-(methylsulfinyl)benzamido]- (8CI)  
MF C15 H13 N O5 S




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Benzoic acid, 5-[[4-[[6-[(4-aminobenzoyl)amino]-1-hydroxy-3-sulfo-2-naphthalenyl]azo]benzoyl]amino]-2-hydroxy-3-methyl-, disodium salt (9CI)  
MF C32 H25 N5 O9 S . 2 Na



● 2 Na


L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid,  
 2-hydroxy-5-[[3-[(2-hydroxy-5,7-disulfo-1-naphthalenyl)azo]-  
 4-methylbenzoyl]amino]-, trisodium salt (9CI)  
 MF C25 H19 N3 O11 S2 . 3 Na




● 3 Na

L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2-(benzoylamino)benzoyl]amino]-2-hydroxy- (9CI)  
 MF C21 H16 N2 O5








L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid,  
 4-[[4-[[3-carboxy-4-hydroxyphenyl]amino]carbonyl]benzoyl]am  
 ino]-2-hydroxy- (9CI)  
 MF C22 H16 N2 O8



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-(4-amino-m-tolamido)-3-chloro- (6CI)  
 MF C15 H13 Cl N2 O4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[3-(carboxymethoxy)-4-[2-hydroxy-6-[2-(2-hydroxy-5-sulfamoylphenylazo)acetoacetamido]-4-sulfo-1-naphthylazo]-7-sulfo-1-naphthylazo]benzamido]- (6CI)  
 MF C46 H35 N9 O19 S3




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[6-[3-[6-(4,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-3-sulfo- (6CI)  
 MF C45 H31 N7 O22 S5

PAGE 1-A





PAGE 1-B



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[6-[3-[6-(2,5-disulfophenylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]- (6CI)  
 MF C41 H29 N7 O19 S4


PAGE 1-A






L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(2,6-difluorobenzoyl)amino]-2-hydroxy-, compd. with  
 1H-imidazole (1:1) (9CI)  
 MF C14 H9 F2 N O4 . C3 H4 N2


CM 1



CM 2




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[(4-methoxybenzoyl)amino]- (9CI)  
 MF C15 H13 N O5  
 CI COM




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[4-amino-3-(carboxymethoxy)-7-sulfo-1-naphthylazo]benzamido]- (6CI)  
 MF C26 H20 N4 O10 S


PAGE 1-A



PAGE 2-A




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 3,3'-[(5-amino-1,3-phenylene)bis(carbonylimino)]bis[6-hydroxy-5-sulfo-, disodium salt (9CI)  
 MF C22 H17 N3 O14 S2 . 2 Na




● 2 Na


L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(4-bromo-2-hydroxybenzoyl)amino]-2-hydroxy-3-methyl- (9CI)  
 MF C15 H12 Br N O5




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-(benzoylamino)-2-hydroxy- (9CI)  
 MF C14 H11 N O4  
 CI COM




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(4-amino-3-methylbenzoyl)amino]-2-hydroxy- (9CI)  
 MF C15 H14 N2 O4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(3-bromobenzoyl)amino]-2-hydroxy- (9CI)  
 MF C14 H10 Br N O4



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[[3-bromobenzoyl]amino]- (9CI)  
 MF C18 H15 N O4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[[3-(trifluoromethyl)benzoyl]amino]- (9CI)  
 MF C15 H10 F3 N O4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[1-hydroxy-6-[3-[5-hydroxy-7-sulfo-6-(8-sulfo-2-naphthylazo)-2-naphthyl]ureido]-3-sulfo-2-naphthylazo]benzamido]- (6CI)  
 MF C45 H31 N7 O16 S3

PAGE 1-A




PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 3-chloro-5-[m-[6-[3-[6-(6,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]- (6CI)  
 MF C45 H30 Cl N7 O19 S4



PAGE 1-A




PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[6-[3-[6-(3,6-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-(6CI)  
 MF C45 H31 N7 O19 S4

PAGE 1-A




PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Salicylic acid, 5-[p-[p-[8-amino-7-[p-[(3-carboxy-4-hydroxyphenyl)carbamoyl]phenylazo]-1-hydroxy-3,6-disulfo-2-naphthylazo]benzamido]phenylazo]- (6CI)  
MF C44 H31 N9 O15 S2

PAGE 1-A




PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Benzoic acid, 5-(benzoylamino)-2-hydroxy-, compd. with 1H-imidazole (1:1)  
(9CI)  
MF C14 H11 N O4 . C3 H4 N2

CM 1




CM 2



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid,  
 5-[p-[6-[2-(o-carboxyphenylazo)acetoacetamido]-1-hydroxy-3-  
 sulfo-2-naphthylazo]benzamido]- (6CI)  
 MF C35 H26 N6 O12 S

PAGE 1-A




PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 3,3'-[1,2-ethanediylbis[oxycarbonylimino-4,1-  
 phenyleneimino(1-hydroxy-3-sulfo-6,2-naphthalenediyl)azo[2-

(carboxymethoxy)-4,1-naphthalenediyl]azo-4,1-phenylenecarbonylimino]]bis[6-hydroxy-, hexasodium salt (9CI)  
MF C88 H64 N14 O26 S2 . 6 Na


PAGE 1-A



PAGE 1-B




PAGE 2-A



● 6 Na


PAGE 2-B



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Strychnidin-10-one, 2,3-dimethoxy-, (+)-5-[(cyanophenylmethyl)amino]-2-hydroxybenzoate (9CI)  
 MF C23 H26 N2 O4 . x C15 H12 N2 O3


CM 1

Rotation (+).




CM 2


Absolute stereochemistry.



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN p-Toluic acid, .alpha.-(3-carboxy-4-hydroxyanilino)- (8CI)  
 MF C15 H13 N O5



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid,  
 5-[[4-[[6-[(4-amino-3-methylbenzoyl)amino]-1-hydroxy-3-sulfo-  
 2-naphthalenyl]azo]-3-methylbenzoyl]amino]-2-hydroxy-, disodium salt  
 (9CI)  
 MF C33 H27 N5 O9 S . 2 Na



●2 Na

L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS


IN Benzoic acid,

5-[[4-[[4-[[6-[[[4-(acetylamino)phenyl]amino]carbonyl]amino]


] -1-hydroxy-3-sulfo-2-naphthalenyl]azo]-2-methylphenyl]azo]benzoyl]amino]-  
2-hydroxy-, disodium salt (9CI)

MF C40 H32 N8 O10 S . 2 Na


PAGE 1-A




●2 Na



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[(2-nitrobenzoyl)amino]- (9CI)  
 MF C14 H10 N2 O6




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,4-dihydroxyphenyl]thioxomethyl]amino]-2-hydroxy- (9CI)  
 MF C14 H11 N O5 S




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid,  
 5-[p-[1-hydroxy-6-[3-[5-hydroxy-7-sulfo-6-(1,5,7-trisulfo-  
 2-naphthylazo)-2-naphthyl]ureido]-3-sulfo-2-naphthylazo]benzamido]- (6CI)  
 MF C45 H31 N7 O22 S5



PAGE 1-A




PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
IN Salicylic acid, 5,5'-[(6-anilino-s-triazine-2,4-diyl)bis[imino-p-phenyleneimino(1-hydroxy-3-sulfo-6,2-naphthylene)azo(3-methoxy-7-sulfo-4,1-naphthylene)azo-p-phenylenecarbonylimino]]di- (6CI)  
MF C91 H66 N18 O24 S4


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 2-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-(p-aminobenzamido)-3-sulfo- (6CI)  
 MF C14 H12 N2 O7 S




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[1-hydroxy-6-[3-[5-hydroxy-7-sulfo-6-(o-sulphophenylazo)-2-naphthyl]ureido]-3-sulfo-2-naphthylazo]benzamido]-(6CI)  
 MF C41 H29 N7 O16 S3

PAGE 1-A




PAGE 1-B




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(3,5-difluorobenzoyl)amino]-2-hydroxy-, compd. with 1H-imidazole (1:1) (9CI)  
 MF C14 H9 F2 N O4 . C3 H4 N2

CM 1




CM 2




CCCCCCCCOC(=O)Nc1ccc(O)c(C(=O)O)c1

PAGE 1-A

Cc1ccc(cc1)C(=O)Nc2ccc(O)c(C(=O)O)c2


```
L3 149 ANSWERS   REGISTRY   COPYRIGHT 2001 ACS
IN  Benzoic acid, 5-[[4-[[2,6-dihydroxy-3-[[2-hydroxy-5-[(3-
    sulfophenyl)azo]phenyl]azo]phenyl]azo]benzoyl]amino]-2-hydroxy-, disodium
MF  salt (9CI)
    C32 H23 N7 O10 S . 2 Na
```

PAGE 1-A




● 2 Na


PAGE 1-B



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 3-chloro-5-[(2,5-dihydroxybenzoyl)amino]-2-hydroxy- (9CI)  
 MF C14 H10 Cl N O6




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-(p-fluorobenzamido)-, monosodium salt (8CI)  
 MF C14 H10 F N O4 . Na




● Na


L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(4-aminobenzoyl)amino]-2-hydroxy-3-methyl- (9CI)  
 MF C15 H14 N2 O4




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[[4-[(3-methylbenzoyl)amino]benzoyl]amino]- (9CI)  
 MF C22 H18 N2 O5



L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(9-anthracenylmethyl)amino]-2-hydroxy- (9CI)  
 MF C22 H17 N O3




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[[2-(phenylmethoxy)benzoyl]amino]- (9CI)  
 MF C21 H17 N O5




L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[1-hydroxy-6-[3-[5-hydroxy-7-sulfo-6-(6-sulfo-2-naphthylazo)-2-naphthyl]ureido]-3-sulfo-2-naphthylazo]benzamido]- (6CI)  
 MF C45 H31 N7 O16 S3


PAGE 1-A









L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN 2,3-Cresotic acid, 5,5'-[sebacoylbis[imino-p-phenyleneimino(1-hydroxy-3-  
 sulfo-6,2-naphthylene)azo[3-(carboxymethoxy)-4,1-naphthylene]azo(3-methyl-  
 p-phenylene)carbonylimino]]di- (6CI)  
 MF C98 H84 N14 O24 S2




PAGE 1-B





PAGE 2-A





L3 149 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[p-[6-[3-[6-(4,8-disulfo-2-naphthylazo)-5-hydroxy-7-sulfo-2-naphthyl]ureido]-1-hydroxy-3-sulfo-2-naphthylazo]benzamido]-(6CI)  
 MF C45 H31 N7 O19 S4



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

184.90

185.05

FILE 'CAPLUS' ENTERED AT 13:09:02 ON 19 JUL 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 19 Jul 2001 VOL 135 ISS 4

FILE LAST UPDATED: 18 Jul 2001 (20010718/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAPLUS now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> d his

(FILE 'HOME' ENTERED AT 13:02:17 ON 19 JUL 2001)

FILE 'REGISTRY' ENTERED AT 13:02:44 ON 19 JUL 2001

L1 STRUCTURE UPLOADED  
L2 0 SEARCH L1 EXACT FULL  
L3 149 SEARCH L1 SSS FULL  
L4 0 DSCAN

FILE 'CAPLUS' ENTERED AT 13:09:02 ON 19 JUL 2001

=> 13

L5 40 L3

=> excitatory

L6 21548 EXCITATORY

=> antagonist

117376 ANTAGONIST

82205 ANTAGONISTS

L7 155601 ANTAGONIST  
(ANTAGONIST OR ANTAGONISTS)

=> 16 and 17

L8 6350 L6 AND L7

=> 15 and 18

L9 0 L5 AND L8

=> neurodegen?

L10 8515 NEURODEGEN?

=> 110 and 15

L11 0 L10 AND L5

=> d 15 1-10logoff hold

'1-10LOGOFF' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

'HOLD' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB

ALL ----- BIB, AB, IND, RE

APPS ----- AI, PRAI

BIB ----- AN, plus Bibliographic Data and PI table (default)

CAN ----- List of CA abstract numbers without answer numbers

CBIB ----- AN, plus Compressed Bibliographic Data

DALL ----- ALL, delimited (end of each field identified)

DMAX ----- MAX, delimited for post-processing

FAM ----- AN, PI and PRAI in table, plus Patent Family data

FBIB ----- AN, BIB, plus Patent FAM

IND ----- Indexing data

IPC ----- International Patent Classifications

MAX ----- ALL, plus Patent FAM, RE

PATS ----- PI, SO

SAM ----- CC, SX, TI, ST, IT

SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)

STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels

IALL ----- ALL, indented with text labels

IBIB ----- BIB, indented with text labels

IMAX ----- MAX, indented with text labels

ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)

OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations

SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms

HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
 containing hit terms  
 HITRN ----- HIT RN and its text modification  
 HITSTR ----- HIT RN, its text modification, its CA index name, and  
 its structure diagram  
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
 its structure diagram  
 KWIC ----- Hit term plus 20 words on either side  
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.  
 ENTER DISPLAY FORMAT (BIB):end

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	6.94	191.99

SESSION WILL BE HELD FOR 60 MINUTES  
 STN INTERNATIONAL SESSION SUSPENDED AT 13:13:15 ON 19 JUL 2001

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal623paz

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
 SESSION RESUMED IN FILE 'CAPLUS' AT 13:18:50 ON 19 JUL 2001  
 FILE 'CAPLUS' ENTERED AT 13:18:50 ON 19 JUL 2001  
 COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	9.87	194.92

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	6.94	191.99

FILE 'REGISTRY' ENTERED AT 13:19:06 ON 19 JUL 2001  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 18 JUL 2001 HIGHEST RN 346684-23-9  
 DICTIONARY FILE UPDATES: 18 JUL 2001 HIGHEST RN 346684-23-9

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=>


Uploading 09557001 open coo and aro.str

L12 STRUCTURE UPLOADED

=> d l12

L12 HAS NO ANSWERS

L12 STR



Structure attributes must be viewed using STN Express query preparation.

=> search

ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):l12

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss

ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full

FULL SEARCH INITIATED 13:20:10 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2753 TO ITERATE

100.0% PROCESSED 2753 ITERATIONS

49 ANSWERS

SEARCH TIME: 00.00.01

L13 49 SEA SSS FUL L12


=> d scan

L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS

IN Benzoic acid, 5-[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
3-phenyl-2-propenyl ester, (E)- (9CI)


MF C23 H21 N O5

Double bond geometry as shown.




HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):49

L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[(9-anthracenylmethyl)amino]-2-hydroxy- (9CI)  
 MF C22 H17 N O3




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 3,3-dimethylbutyl ester (9CI)  
 MF C20 H25 N O5







L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 3-phenylbutyl ester (9CI)  
 MF C24 H25 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[[[2-hydroxyphenyl)methyl]amino]- (9CI)  
 MF C14 H13 N O4




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 cyclohexylmethyl ester (9CI)  
 MF C21 H25 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid,  
 5-[[[3'-(aminomethyl)[1,1'-biphenyl]-3-yl]methyl]amino]-  
 2-[[1-(1-iminoethyl)-4-piperidinyloxy]-, ethyl ester (9CI)  
 MF C30 H35 N5 O3




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 3,7-dimethyloctyl ester (9CI)  
 MF C24 H33 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[(2,5-dimethoxyphenyl)methyl]amino]-2-hydroxy- (9CI)  
 MF C16 H17 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[[3-hydroxyphenyl)methyl]amino]-, methyl ester (9CI)  
 MF C15 H15 N O4



L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-, (3,5-dimethylphenyl)methyl ester (9CI)  
 MF C23 H23 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[[p-(aminomethyl)benzyl]amino]-, methyl ester, dihydrochloride (8CI)  
 MF C16 H18 N2 O3 . 2 Cl H




● 2 HCl


L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,5-dihydroxyphenyl]methyl]amino]-2-hydroxy-,  
 phenylmethyl ester (9CI)  
 MF C21 H19 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[5-(4-amino-1,4-dioxobutoxy)-2-hydroxyphenyl]  
 methyl]amino]-2-hydroxy- (9CI)  
 MF C18 H18 N2 O7




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,5-dihydroxyphenyl]methyl]amino]-2-hydroxy-, methyl  
 ester (9CI)  
 MF C15 H15 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 3,5,5-trimethylhexyl ester (9CI)  
 MF C23 H31 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[(p-fluorobenzyl)amino]-, methyl ester (8CI)  
 MF C15 H14 F N O3




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-, phenyl  
 ester (9CI)  
 MF C20 H17 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,4-dihydroxyphenyl]methyl]amino]-2-hydroxy- (9CI)  
 MF C14 H13 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,5-dihydroxyphenyl]methyl]amino]-2-methoxy-, methyl ester (9CI)  
 MF C16 H17 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,5-dihydroxyphenyl]methyl]amino]-2-hydroxy-, hexadecyl ester (9CI)  
 MF C30 H45 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN p-Toluic acid, .alpha.-(3-carboxy-4-hydroxyanilino)- (8CI)  
 MF C15 H13 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 [1,1'-biphenyl]-4-yl ester (9CI)  
 MF C26 H21 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[[2-hydroxy-1-naphthalenyl)methyl]amino]-  
 (9CI)  
 MF C18 H15 N O4



L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 1,1-dimethylethyl ester (9CI)  
 MF C18 H21 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 2-methyl-3-phenylpropyl ester (9CI)  
 MF C24 H25 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS




IN Benzoic acid, 5-[[ (2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy- (9CI)  
 MF C14 H13 N O5  
 CI COM




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[ (2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 2-naphthalenyl ester (9CI)  
 MF C24 H19 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid,  
 5-[[[3'-(aminoiminomethyl)[1,1'-biphenyl]-3-yl]methyl]amino]-  
 2-(4-piperidinyloxy)-, ethyl ester (9CI)  
 MF C28 H32 N4 O3




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[ (2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 2,4,4-trimethylpentyl ester (9CI)  
 MF C22 H29 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 3-hydroxyphenyl ester (9CI)  
 MF C20 H17 N O6




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[[2-hydroxyphenyl)methyl]amino]-, methyl ester  
 (9CI)  
 MF C15 H15 N O4




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 [4-(1-methylethyl)phenyl]methyl ester (9CI)  
 MF C24 H25 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid,  
 5-[[[3'-(aminoiminomethyl)[1,1'-biphenyl]-3-yl]methyl]amino]-  
 2-[[[1-(1-iminoethyl)-4-piperidinyloxy]- (9CI)  
 MF C28 H31 N5 O3




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 2-phenylethyl ester (9CI)  
 MF C22 H21 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[2,5-dimethoxyphenyl)methyl]amino]-2-methoxy- (9CI)  
 MF C17 H19 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 2-hydroxy-5-[[[4-hydroxyphenyl)methyl]amino]-, methyl ester  
 (9CI)  
 MF C15 H15 N O4




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 3-phenylpropyl ester (9CI)  
 MF C23 H23 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[[p-[(dimethylamino)methyl]benzyl]amino]-, methyl ester  
 (8CI)  
 MF C18 H22 N2 O3




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[ (2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 2-tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylethyl ester (9CI)  
 MF C26 H31 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[ (2,3-dihydroxyphenyl)methyl]amino]-2-hydroxy- (9CI)  
 MF C14 H13 N O5



L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[ (2,5-dimethoxyphenyl)methyl]amino]-2-hydroxy-, methyl  
 ester (9CI)  
 MF C17 H19 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[ (2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 hydrochloride (9CI)  
 MF C14 H13 N O5 . Cl H




● HCl


L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[(p-fluorobenzyl)amino]- (8CI)  
 MF C14 H12 F N O3




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 1-naphthalenyl ester (9CI)  
 MF C24 H19 N O5




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[4-(diethylamino)-2-hydroxyphenyl]methyl]amino]-2-  
 hydroxy- (9CI)  
 MF C18 H22 N2 O4




L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-, ethyl  
 ester (9CI)  
 MF C16 H17 N O5



L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Benzoic acid, 5-[[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-,  
 4-phenylbutyl ester (9CI)  
 MF C24 H25 N O5



L13 49 ANSWERS REGISTRY COPYRIGHT 2001 ACS  
 IN Salicylic acid, 5-[(p-carbamoylbenzyl)amino]-, methyl ester (8CI)  
 MF C16 H16 N2 O4



ALL ANSWERS HAVE BEEN SCANNED

=> file ca plus

'PLUS' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):end

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

134.80

326.79

FILE 'CAPLUS' ENTERED AT 13:21:52 ON 19 JUL 2001

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 19 Jul 2001 VOL 135 ISS 4

FILE LAST UPDATED: 18 Jul 2001 (20010718/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAPLUS now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying,



or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> l13

L14 17 L13

=> d l13 1-17 ti

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> d l14 1-17 ti

L14 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Preparation of piperidinyloxyamidinophenylpropenylbenzenamines as anticoagulants.

L14 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Isoquinolinesulphonamide derivatives inhibit transcriptional elongation of human immunodeficiency virus type 1 RNA in a promyelocytic model of latency

L14 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Synthesis and application of chromogens used for the determination of hydrogen peroxide, peroxidases, oxidases in hydrogen peroxide forming systems

L14 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Synthesis and biological activity of 5-[(2,5-dihydroxybenzyl)amino]salicylic acid analogs as inhibitors of EGF receptor-associated protein tyrosine kinase

L14 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Skin-lightening and wrinkle-preventing cosmetics containing hydroxybenzoic acids

L14 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI A Versatile Solid Phase Synthesis of Lavendustin A and Certain Biologically Active Analogs

L14 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Structural requirements for the antimitotic mode of action of SDZ LAP 977

L14 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Solid Phase Synthesis of Lavendustin A and Analogs

L14 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Novel Antiproliferative Agents Derived from Lavendustin A

L14 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Structure-Activity Relationships in a Series of 5-[(2,5-Dihydroxybenzyl)amino]salicylate Inhibitors of EGF-Receptor-Associated Tyrosine Kinase: Importance of Additional Hydrophobic Aromatic Interactions

L14 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Preparation of dihydroxybenzylamine derivatives as drugs.

L14 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2001 ACS  
 TI Bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors

L14 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2001 ACS  
 TI Synthesis and structure-activity studies of a series of [(hydroxybenzyl)amino]salicylates as inhibitors of EGF receptor-associated tyrosine kinase activity

L14 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2001 ACS  
 TI Non-amine based analogs of lavendustin A as protein-tyrosine kinase inhibitors

L14 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2001 ACS  
 TI Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors

L14 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2001 ACS  
 TI Isolation of a novel tyrosine kinase inhibitor, lavendustin A, from Streptomyces griseolavendus

L14 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2001 ACS  
 TI Substituted salicylic acids and their use in pharmaceutical drugs

=> d 114 17 ti fbib abs

L14 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2001 ACS  
 TI Substituted salicylic acids and their use in pharmaceutical drugs  
 AN 1971:405498 CAPLUS  
 DN 75:5498  
 TI Substituted salicylic acids and their use in pharmaceutical drugs  
 IN Shen, Tsung-Ying; Walford, Gordon L.; Witzel, Bruce E.; Jones, Howard  
 PA Merck and Co., Inc.  
 SO Ger. Offen., 32 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2031227	A	19710107	DE 1970-2031227	19700624
				US 1969-836623	19690625
				US 1970-30322	19700420
	US 3632760	A	19720104	US 1969-836623	19690625
	US 3674844	A	19720704	US 1970-30322	19700420
	NL 7008623	A	19701229	NL 1970-8623	19700612
				US 1969-836623	19690625
				US 1970-30322	19700420
	GB 1268465	A	19720329	GB 1970-1268465	19700618
				US 1969-836623	19690625
				US 1970-30322	19700420
	JP 49020197	B4	19740523	JP 1970-53582	19700622
				US 1969-836623	19690625
				US 1970-30322	19700420
	CH 536278	A	19730615	CH 1970-9503	19700623
				US 1969-836623	19690625

FR 2053015

A5 19710416

US 1970-30322 19700420

FR 1970-23328 19700624

US 1969-836623 19690625

GI For diagram(s), see printed CA Issue.

AB The title compds. (I, Y = CH<sub>2</sub>NH, NHCH<sub>2</sub>, CH:N, N:CH, CONH, or NHCO, R = OH or NH<sub>2</sub>, R<sub>1</sub> = H or low alkyl, R<sub>2</sub> = H, low alkyl, or F; X = H, low alkoxy, F, fluoroalkyl, or dialkylamino) are prepd. by 3 methods: a BzH deriv. with an aminosalicylic acid, followed by hydrogenation; treating a (halomethyl)salicylic acid with a PhNH<sub>2</sub> deriv.; or demethylation of a substituted benzamidoanisole and subsequent carboxylation. I are antiinflammatory.

=&gt; d 114 3,7,8,9,10 ti fbib abs

L14 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Synthesis and application of chromogens used for the determination of hydrogen peroxide, peroxidases, oxidases in hydrogen peroxide forming systems

AN 1999:635578 CAPLUS

DN 131:254664

TI Synthesis and application of chromogens used for the determination of hydrogen peroxide, peroxidases, oxidases in hydrogen peroxide forming systems

IN Krieg, Reimar; Halbhuber, Karl-Juergen

PA Friedrich-Schiller-Universitaet Jena, Germany

SO Ger. Offen., 36 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19813979	A1	19990930	DE 1998-19813979	19980328

AB The invention concerns the synthesis of novel chromogens/fluorogens that are used for the quantitation of hydrogen peroxide, peroxidase and oxidase in hydrogen peroxide forming systems, e.g. enzyme immunoassays and immunohistochem. staining. Substances of the general formula  $\{[Z-NHRa1-CHR2R3]a+\}nAa(a+n)-$  are prepd. and applied; Ar = aryl, heteroaryl, mono or higher substituted chelate-forming cyclic or aliph. ligand; a = 0,1; n = 1,2,...; R<sub>2</sub>,R<sub>3</sub> = benzene, pyridine, pyrrole, furan, thiofuran derivs., metallocene; A = anion, e.g. halogen, acetate, trifluoroacetate, or BF<sub>4</sub>. Synthesis of the color forming substances is disclosed. Reagents for the peroxide assay contain the chromophores, buffers, salts of transition metals, addnl. electron-rich systems, that are electron donors or radical transfer mediators.

RE.CNT 5

RE

(1) Anon; EP 0152253 A2 CAPLUS

(2) Anon; EP 0194084 A2 CAPLUS

(3) Anon; DE 2366191 B1 CAPLUS

(4) Anon; DE 3124594 A1 CAPLUS

(5) Anon; DE 4029709 A1 CAPLUS

L14 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Structural requirements for the antimitotic mode of action of SDZ LAP 977

AN 1996:577182 CAPLUS

DN 125:292290

TI Structural requirements for the antimitotic mode of action of SDZ LAP 977  
AU Nussbaumer, Peter; Winiski, Anthony P.; Stuetz, Anton  
CS Department General Dermatology, Sandoz Research Institute, Vienna,  
A-1235,

Austria

SO Sci. Pharm. (1996), 64(3/4), 601-608

CODEN: SCPHA4; ISSN: 0036-8709

DT Journal

LA English

AB Derivs. of SDZ LAPO 977 (I) were prepd. and the antimitotic and  
antiproliferative activity against HaCaT cells was tested. The analogs  
of

lavendustin A lacked inhibitory activity against Tyr kinase, but exerted  
an antimitotic mode of action. The 2,5-dihydroxy substituted compds. did  
not exert antimitotic activity. The methylation of 1 OH group of the  
hydroquinone moiety was sufficient for inducing mitotic arrest at concns.  
near the antiproliferative IC50 values. Addnl. methylation of the 2nd OH  
group resulted in substantially improved antiproliferative potency with  
the same mode of action. Esterification increased the antiproliferative  
potency, but was not essential for antimitotic activity of I-related  
compds.

L14 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Solid Phase Synthesis of Lavendustin A and Analogs

AN 1995:629844 CAPLUS

DN 123:83028

TI Solid Phase Synthesis of Lavendustin A and Analogs

AU Green, Jeremy

CS ARIAD Pharmaceuticals Inc., Cambridge, MA, 02139, USA

SO J. Org. Chem. (1995), 60(13), 4287-90

CODEN: JOCEAH; ISSN: 0022-3263

DT Journal

LA English

AB A method has been developed for the solid phase synthesis of the tyrosine  
kinase inhibitor lavendustin A and related compds. This chem. has been  
applied to the combinatorial synthesis of 60 analogs of lavendustin A

with

good efficiency. The individual syntheses of lavendustin A,  
tetra-O-methylated lavendustin A and tetra-O-methylated lavendustin A  
amide are described, as well as the combinatorial synthesis of the  
analogs.

L14 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Novel Antiproliferative Agents Derived from Lavendustin A

AN 1995:196605 CAPLUS

DN 122:9738

TI Novel Antiproliferative Agents Derived from Lavendustin A

AU Nussbaumer, Peter; Winiski, Anthony P.; Cammisuli, Salvatore; Hiestand,  
Peter; Weckbecker, Gisbert; Stuetz, Anton

CS Department of Dermatology, SANDOZ Research Institute, Vienna, A-1235,  
Austria

SO J. Med. Chem. (1994), 37(24), 4079-84

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

AB The active partial structure of the potent tyrosine kinase inhibitor  
lavendustin A was derivatized in the search for novel agents against  
cellular proliferation. The antiproliferative potential of the new  
derivs. 2,5-(RO)2C6H3XC6H3(OH)CO2R1-4,3 [I, R, R1 = Me, H; X = CH2NH,

NHCH<sub>2</sub>, CH<sub>2</sub>O, OCH<sub>2</sub>, CH:CH, CH<sub>2</sub>CH<sub>2</sub>] was detd. using the human keratinocyte cell line HaCaT as the primary test system. Whereas I [ X = CH<sub>2</sub>NH, R =

R1

= H] were ineffective in inhibiting cell proliferation, esterification of their carboxylic acid function leads to measurable antiproliferative activity. Addnl. O-methylation of the 2,5-dihydroxyphenyl moiety yields activity in the micromolar range. Further substantial increases in activity are achieved with I [R = Me, R1 = H, Me, X = CH<sub>2</sub>O, OCH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>] leading to I [X = CH<sub>2</sub>CH<sub>2</sub>, R = R1 = Me] as the most potent analog identified to date. These increases in antiproliferative activity are paralleled, however, by the disappearance of activity against the epidermal growth factor receptor-assocd. tyrosine kinase, suggesting another mechanism of action.

L14 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2001 ACS

TI Structure-Activity Relationships in a Series of 5-[(2,5-Dihydroxybenzyl)amino]salicylate Inhibitors of EGF-Receptor-Associated Tyrosine Kinase: Importance of Additional Hydrophobic Aromatic Interactions

AN 1994:322877 CAPLUS

DN 120:322877

TI Structure-Activity Relationships in a Series of 5-[(2,5-Dihydroxybenzyl)amino]salicylate Inhibitors of EGF-Receptor-Associated Tyrosine Kinase: Importance of Additional Hydrophobic Aromatic Interactions

AU Chen, Huixiong; Boiziau, Janine; Parker, Fabienne; Mailliet, Patrick; Commercon, Alain; Tocque, Bruno; Le Pecq, Jean-Bernard; Roques, Bernard-Pierre; Garbay, Christiane

CS Departement de Pharmacochimie Moleculaire et Structurale, Faculte de Pharmacie, Paris, 75270, Fr.

SO J. Med. Chem. (1994), 37(6), 845-59

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

AB Potent inhibitors of EGF-dependent protein tyrosine kinase (PTK) activity were synthesized in a series of

5-[(2,5-dihydroxybenzyl)amino]salicylates.

Several of these compds. inhibited EGF-dependent DNA synthesis in ER 22 cells with IC<sub>50</sub> < 1 .mu.M. In this series of PTK inhibitors, the role of the salicylate moiety as a potential divalent ion chelator was tested and found to be nonessential in all cases. The length of the substituting carboxyl group were investigated to improve cellular bioavailability, and this anal. provided compds. with increased inhibitory effect on EGF-induced DNA synthesis. Salicylates esterified with long hydrophobic chains were noncompetitive inhibitors of ATP, in contrast to the free

acid

and Me salicylate. Moreover, all the tested inhibitors were shown to be noncompetitive inhibitors of the peptide substrate. Structure-activity relationships allowed the authors to suspect a hydrophobic pocket in the tyrosine kinase domain, preferentially interacting with arom. rings. Finally, the selectivity of the best inhibitors was tested against other kinases, and they were selective for tyrosine kinase. They were also

good

inhibitors of EGF-receptor autophosphorylation.

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:ssspal623paz

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 13:41:21 ON 19 JUL 2001  
FILE 'CAPLUS' ENTERED AT 13:41:21 ON 19 JUL 2001  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.19	350.98
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.53	-3.53

=> d his

(FILE 'HOME' ENTERED AT 13:02:17 ON 19 JUL 2001)

FILE 'REGISTRY' ENTERED AT 13:02:44 ON 19 JUL 2001

L1 STRUCTURE UPLOADED  
L2 0 SEARCH L1 EXACT FULL  
L3 149 SEARCH L1 SSS FULL  
L4 0 DSCAN

FILE 'CAPLUS' ENTERED AT 13:09:02 ON 19 JUL 2001

L5 40 L3  
L6 21548 EXCITATORY  
L7 155601 ANTAGONIST  
L8 6350 L6 AND L7  
L9 0 L5 AND L8  
L10 8515 NEURODEGEN?  
L11 0 L10 AND L5

FILE 'REGISTRY' ENTERED AT 13:19:06 ON 19 JUL 2001

L12 STRUCTURE UPLOADED  
L13 49 SEARCH L12 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:21:52 ON 19 JUL 2001

L14 17 L13

=> NMDA

17393 NMDA  
2 NMDAS  
L15 17393 NMDA  
(NMDA OR NMDAS)

=> l15 and l14

L16 1 L15 AND L14

=> d l16 ti fbib abs

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

TI Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors

AN 1992:4282 CAPLUS

DN 116:4282  
 TI Long-term potentiation in the hippocampus is blocked by tyrosine kinase inhibitors  
 AU O'Dell, Thomas J.; Kandel, Eric R.; Grant, Seth G. N.  
 CS Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA  
 SO Nature (London) (1991), 353(6344), 558-60  
 CODEN: NATUAS; ISSN: 0028-0836

DT Journal  
 LA English

AB Long-term potentiation (LTP) in the hippocampus is thought to contribute to memory formation. In the CA1 region, LTP requires the **NMDA** (N-methyl-D-aspartate) receptor-dependent influx of Ca<sup>2+</sup> and activation of

serine and threonine protein kinases. Because of the high amt. of protein

tyrosine kinases in hippocampus and cerebellum, 2 regions implicated in learning and memory, the possible addnl. requirement of tyrosine kinase activity in LTP was examd. The specificity in brain of 5 inhibitors of tyrosine kinase was examd. and 2 of them, lavendustin A and genistein, showed substantially greater specificity for tyrosine kinase from hippocampus than for 3 serine-threonine kinases: protein kinase A,

protein kinase C, and Ca<sup>2+</sup>/calmodulin kinase II. Lavendustin A and genistein selectively blocked the induction of LTP when applied in the bath or injected into the postsynaptic cell. By contrast, the inhibitors had no effect on the established LTP, on normal synaptic transmission, or on the neurotransmitter actions attributable to the actions of protein kinase A or protein kinase C. These data suggest that tyrosine kinase activity could be required postsynaptically for long-term synaptic plasticity in the hippocampus. As Ca<sup>2+</sup>-calmodulin kinase II or protein kinase C seem to also be required, the tyrosine kinases could participate postsynaptically in a kinase network together with serine and threonine kinases.

=> Zn or zinc

364258 ZN  
 20346 ZNS  
 379982 ZN  
 (ZN OR ZNS)  
 394766 ZINC  
 69 ZINCS  
 394782 ZINC  
 (ZINC OR ZINCS)

L17 564689 ZN OR ZINC

=> L5 and l14

L18 14 L5 AND L14

=> l18 not l15

L19 13 L18 NOT L15

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	34.61	361.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION

CA SUBSCRIBER PRICE

-4.12

-4.12

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 13:48:06 ON 19 JUL 2001

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:x  
LOGINID:sssptal623paz  
PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'CAPLUS' AT 13:58:48 ON 19 JUL 2001  
FILE 'CAPLUS' ENTERED AT 13:58:48 ON 19 JUL 2001  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	34.61	361.40
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.12	-4.12

=> d id  
'ID' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB  
ALL ----- BIB, AB, IND, RE  
APPS ----- AI, PRAI  
BIB ----- AN, plus Bibliographic Data and PI table (default)  
CAN ----- List of CA abstract numbers without answer numbers  
CBIB ----- AN, plus Compressed Bibliographic Data  
DALL ----- ALL, delimited (end of each field identified)  
DMAX ----- MAX, delimited for post-processing  
FAM ----- AN, PI and PRAI in table, plus Patent Family data  
FBIB ----- AN, BIB, plus Patent FAM  
IND ----- Indexing data  
IPC ----- International Patent Classifications  
MAX ----- ALL, plus Patent FAM, RE  
PATS ----- PI, SO  
SAM ----- CC, SX, TI, ST, IT  
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;  
SCAN must be entered on the same line as the DISPLAY,  
e.g., D SCAN or DISPLAY SCAN)  
STD ----- BIB, IPC, and NCL  
  
IABS ----- ABS, indented with text labels  
IALL ----- ALL, indented with text labels  
IBIB ----- BIB, indented with text labels  
IMAX ----- MAX, indented with text labels  
ISTD ----- STD, indented with text labels  
  
OBIB ----- AN, plus Bibliographic Data (original)  
OIBIB ----- OBIB, indented with text labels



SBIB ----- BIB, no citations  
 SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms  
 HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)  
                   containing hit terms  
 HITRN ----- HIT RN and its text modification  
 HITSTR ----- HIT RN, its text modification, its CA index name, and  
                   its structure diagram  
 FHITSTR ----- First HIT RN, its text modification, its CA index name, and  
                   its structure diagram  
 KWIC ----- Hit term plus 20 words on either side  
 OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.  
 ENTER DISPLAY FORMAT (BIB):end

=> d 114 13 ti fbib abs

L14 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2001 ACS  
 TI Synthesis and structure-activity studies of a series of  
   [(hydroxybenzyl)amino]salicylates as inhibitors of EGF  
 receptor-associated  
   tyrosine kinase activity  
 AN 1994:131 CAPLUS  
 DN 120:131  
 TI Synthesis and structure-activity studies of a series of  
   [(hydroxybenzyl)amino]salicylates as inhibitors of EGF  
 receptor-associated  
   tyrosine kinase activity  
 AU Chen, Huixiong; Boiziau, Janine; Parker, Fabienne; Maroun, Rachid;  
 Tocque,  
   Bruno; Roques, Bernard P.; Garbay-Jaureguiberry, Christiane  
 CS Dep. Pharmacochim. Mol. Struct., INSERM, Paris, 75270, Fr.  
 SO J. Med. Chem. (1993), 36(25), 4094-8  
   CODEN: JMCMAR; ISSN: 0022-2623  
 DT Journal  
 LA English  
 AB The synthesis and structure-activity relations of  
   [()hydroxybenzylidene)amino]-salicylates and  
   [(hydroxybenzyl)amino]salicyla  
   tes as inhibitors of EGF receptor-assocd. tyrosine kinase activity are  
   described. Their inhibitory potency was evaluated in vitro using ER 22  
   cell membranes (CCl 39 cells transfected with EGF receptor) as an enzyme  
   source and the tridecapeptide RRSrc (RRLIEDAEYAARG) as substrate. Their  
   cellular activity was measured by inhibition of the EGF-stimulated DNA  
   synthesis of ER 22 cells. Chem. modifications were made to analyze the  
   role of the different substituents. The amino series was found to be  
 more  
   active than the imino series. The hydroquinone moiety appears to be

essential for tyrosine kinase inhibitory activity in 5-[(2,5-dihydroxybenzyl)amino]salicylates. Comparison of the imino and amino series by mol. modeling techniques provides further evidence in support of the hypothesis that the important reduced linking chain, CH2NH, allows the correct positioning of the 2,5-dihydroxybenzyl ring, possibly in a cis-like conformational arrangement.

=> tyrosine kinase  
105727 TYROSINE  
2037 TYROSINES  
106174 TYROSINE  
(TYROSINE OR TYROSINES)  
156946 KINASE  
32142 KINASES  
162761 KINASE  
(KINASE OR KINASES)  
L20 24156 TYROSINE KINASE  
(TYROSINE(W) KINASE)

=> alzheimer?  
L21 19386 ALZHEIMER?

=> l21 and l20  
L22 105 L21 AND L20

=> d his

(FILE 'HOME' ENTERED AT 13:02:17 ON 19 JUL 2001)

FILE 'REGISTRY' ENTERED AT 13:02:44 ON 19 JUL 2001  
L1 STRUCTURE UPLOADED  
L2 0 SEARCH L1 EXACT FULL  
L3 149 SEARCH L1 SSS FULL  
L4 0 DSCAN

FILE 'CAPLUS' ENTERED AT 13:09:02 ON 19 JUL 2001  
L5 40 L3  
L6 21548 EXCITATORY  
L7 155601 ANTAGONIST  
L8 6350 L6 AND L7  
L9 0 L5 AND L8  
L10 8515 NEURODEGEN?  
L11 0 L10 AND L5

FILE 'REGISTRY' ENTERED AT 13:19:06 ON 19 JUL 2001  
L12 STRUCTURE UPLOADED  
L13 49 SEARCH L12 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:21:52 ON 19 JUL 2001  
L14 17 L13  
L15 17393 NMDA  
L16 1 L15 AND L14  
L17 564689 ZN OR ZINC  
L18 14 L5 AND L14  
L19 13 L18 NOT L15  
L20 24156 TYROSINE KINASE

L21 19386 ALZHEIMER?  
L22 105 L21 AND L20

=> 117 and 120

L23 147 L17 AND L20

=> 122 and 123

L24 1 L22 AND L23

=> d 124 ti fbib abs

L24 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

TI Drastic reduction of the **zinc**- and magnesium-stimulated protein **tyrosine kinase** activities in **Alzheimer's** disease hippocampus

AN 1993:601105 CAPLUS

DN 119:201105

TI Drastic reduction of the **zinc**- and magnesium-stimulated protein **tyrosine kinase** activities in **Alzheimer's** disease hippocampus

AU Vener, Alexander V.; Aksenova, Marina V.; Burbaeva, Gulnur Sh.

CS A.N. Belozersky Institute of Physico-Chemical Biology, Moscow State University, Moscow, Russia

SO FEBS Lett. (1993), 328(1-2), 6-8

CODEN: FEBLAL; ISSN: 0014-5793

DT Journal

LA English

AB Tyrosine phosphorylation of proteins from postmortem hippocampi of five **Alzheimer's** disease and five control cases have been compared. It was found that addn. of Zn<sup>2+</sup> or Mg<sup>2+</sup> to membrane fractions of control hippocampi caused the phosphorylation of 32-, 40-, 55-, 60-, 80- and 100-kDa proteins or 43-, 55-, 60- and 90-kDa proteins, resp. The phosphorylation of all these proteins is shown to be drastically reduced in **Alzheimer's** disease hippocampi. Vanadate, an inhibitor of protein tyrosine phosphatases, had no influence on the level of protein phosphorylation. Western blot anal. did not reveal any differences in

the

anti-phosphotyrosine immunoreactive membrane proteins from **Alzheimer's** disease and control hippocampi. **Tyrosine kinase** activity of immunopptd. p60c-src from **Alzheimer's** disease and control hippocampi were the same. In conclusion, the Zn<sup>2+</sup>- and Mg<sup>2+</sup>-stimulated **tyrosine kinase** activities, distinct from activity of p60c-src, are decreased in **Alzheimer's** disease hippocampus.

=> 115 and 120

L25 119 L15 AND L20

=> aminosalicylic

L26 4251 AMINOSALICYLIC

=> neuro?

L27 358651 NEURO?

=> 126 and 127

L28 26 L26 AND L27

=> neurotoxicity

12838 NEUROTOXICITY  
70 NEUROTOXICITIES  
L29 12859 NEUROTOXICITY  
(NEUROTOXICITY OR NEUROTOXICITIES)

=> 128 and 129

L30 2 L28 AND L29

=> d 130 ti fbib abs

L30 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2001 ACS  
TI Studies on the melanin affinity of selegiline (deprenyl) and other amphetamine derivatives  
AN 1988:49174 CAPLUS  
DN 108:49174  
TI Studies on the melanin affinity of selegiline (deprenyl) and other amphetamine derivatives  
AU Bathory, Gabor; Szuts, Tamas; Magyar, Kalman  
CS Dep. Pharmacodyn., Semmelweis Med. Sch., Budapest, H-1445, Hung.  
SO Pol. J. Pharmacol. Pharm. (1987), 39(2), 195-201  
CODEN: PJPPAA; ISSN: 0301-0244  
DT Journal  
LA English  
AB The in vivo melanin binding of [14C]selegiline was studied in mice. Extensive accumulation was obsd. in the pigmented mouse eye, while in the albino animal uptake was low in the corresponding tissues. In vitro investigations demonstrated that the amphetamine derivs. tested can be taken up by melanins. Scatchard anal. of selegiline binding to dopamine melanin (structurally similar to **neuromelanin**) and beef eye melanin showed that >1 class of binding sites may be involved. The total binding capacity of the beef eye melanin was higher than that of the dopamine melanin. Selegiline inhibited the binding of the **neurotoxic** metabolite of MPTP to dopamine melanin. Selegiline may accumulate in pigmented nerve cells. Melanin affinity may contribute to the use of this compd. for the treatment of Parkinson's disease or may play a role in its protective effect against MPTP **neurotoxicity**.

=> d 130 ti 2 fbib abs

L30 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2001 ACS  
TI **Neurotoxicity** of dihydrostreptomycin; effects of longer term therapy  
AN 1952:21201 CAPLUS  
DN 46:21201  
OREF 46:3648i,3649a  
TI **Neurotoxicity** of dihydrostreptomycin; effects of longer term therapy  
AU O'Connor, John B.; Christie, Frederick J.; Howlett, Kirby S., Jr.  
SO Am. Rev. Tuberc. (1951), 63, 312-24  
DT Journal  
LA Unavailable  
AB The toxic effects of streptomycin (I) and of dihydrostreptomycin (II) were studied in 55 patients treated with one or the other of these drugs together with p-**aminosalicylic** acid concurrently. Toxic manifestations increased when patients were treated continuously for 6 months or more with daily doses of 1.5 g. or less of I. The principal toxic manifestation with I was impairment of labyrinthine function and

that with II was impairment of hearing.

=> d 128 1-10 ti

L28 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI Effects of chondroitin sulfate on colitis induced by dextran sulfate sodium in rats

L28 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI Comparative tolerability of treatments for inflammatory bowel disease

L28 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI Crohn's disease: How to prevent a flare-up

L28 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI Preparation of solid porous matrixes for pharmaceutical uses

L28 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI Soluble mediators and the interaction of drugs in IBD

L28 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI Preparation of steroid-containing sialic acid amide derivatives enhancing a choline acetyltransferase activity in cholinergic **neurons**

L28 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI Substituted benzamides, radioligand analogs, preparation, and methods for identifying 5-HT<sub>3</sub> receptors and detection and treatment of abnormal conditions assocd. therewith

L28 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI Preparation and in vitro pharmacology of 5-HT<sub>4</sub> receptor ligands. Partial agonism and antagonism of metoclopramide analogous benzoic esters

L28 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI Preparation of N-phenyl-N'-heteroaryllureas as 5HT<sub>2C</sub> receptor antagonists

L28 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI cis- and trans-derivatives of N-[(1,4-dialkyl-6-arylpiperazine-2-yl)methyl]benzamides as 5-HT<sub>3</sub> receptor antagonists

=> d 128 11-26 ti

L28 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI Oxidant-evoked release of acetylcholine from enteric **neurons** of the rat colon

L28 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI Pharmaceuticals in the treatment of symptoms of disorders related to **neurological** diseases and etiologically related symptomology

L28 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI The effects of PAS sodium on the levels of monoamine **neurotransmitter** in different brain regions of manganese exposed rats

L28 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI Preparation of (N-azabicyclononylcarboxamido)benzoxepins as serotonin 5HT<sub>3</sub>

antagonists

- L28 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2001 ACS  
TI Sustained-release pharmaceutical matrixes containing polymer blends having reverse phase morphology and giving a zero-order rate
- L28 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2001 ACS  
TI Long-lasting agonist activity produced by a capsaicin-like photoaffinity probe
- L28 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2001 ACS  
TI High-performance liquid chromatographic assay of 5-**aminosalicylic** acid and its acetylated metabolite in biological fluids using electrochemical detection
- L28 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2001 ACS  
TI Studies on the melanin affinity of selegiline (deprenyl) and other amphetamine derivatives
- L28 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2001 ACS  
TI Potentiation of the contractile activity of agonists acting on histamine receptors by metronidazole and 5-**aminosalicylic** acid on the guinea-pig ileum
- L28 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2001 ACS  
TI Metronidazole and 5-**aminosalicylic** acid enhance the contractile activity of histaminergic agonists on the guinea pig isolated ileum
- L28 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2001 ACS  
TI Detection of some pharmaceutical primary aromatic amines, tranquilizers and sedatives
- L28 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2001 ACS  
TI Enzyme-linked immunosorbent assay (ELISA) for antimyelin basic protein antibody and its application to studies of experimental allergic encephalomyelitis
- L28 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2001 ACS  
TI Effect of pasacaine on some functions of the central nervous system
- L28 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2001 ACS  
TI The effects of antituberculous drugs on the hemobacteriostatic power of tuberculous patients. An inquiry into the protective mechanism of the human body and **neurohumoral** factors working in it
- L28 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2001 ACS  
TI Convulsant action of p-**aminosalicylic** acid
- L28 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2001 ACS  
TI **Neurotoxicity** of dihydrostreptomycin; effects of longer term therapy

=> histaminergic agonists

1575 HISTAMINERGIC  
3 HISTAMINERGICS  
1576 HISTAMINERGIC  
(HISTAMINERGIC OR HISTAMINERGICS)

## 55614 AGONISTS

L31 25 HISTAMINERGIC AGONISTS  
(HISTAMINERGIC (W) AGONISTS)

=> l21 and l31

L32 0 L21 AND L31

=> d l28 25-26 ti fbib abs

L28 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI Convulsant action of p-**aminosalicylic** acid

AN 1954:69108 CAPLUS

DN 48:69108

OREF 48:12314e-i

TI Convulsant action of p-**aminosalicylic** acid

AU Scarinci, V.

CS Univ. Bologna

SO Arch. sci. biol. (Italy) (1952), 36, 394-404

DT Journal

LA Unavailable

AB p-**Aminosalicylic** acid (I) applied directly to various regions of the nervous system in the toad (*Bufo viridis*), the frog (*Rana esculenta*), the pigeon, the rabbit, and the dog produced an epileptic state or hyperexcitability followed in some cases by a flaccid paralysis. These effects were not caused by the osmotic pressure of the solns. applied since solns. of NaCl and of Na salicylate at the same concn. produced no effect. The pronounced action on the nervous system appeared to be assocd. with the mol. configuration of the mol. An NH<sub>2</sub> group para to the carboxylic group seems to be the structure responsible for the **neurotropic** properties of I. Reactions to I depended both on the species and on the region applied. Local application to the dorsal surface of the spinal cord of the toad produced in order, increase in reflex excitability, tetanus, and finally flaccid paralysis. In both the frog and the toad I applied locally to the bulb caused paralysis. In

dogs

application of I to various regions of the brain caused clonus in the muscles under control of that region. Application to the zygomatic-temporal region decreased chronaxy in the area controlled by this region. Dogs made susceptible by pharmacological means to reflex epilepsy were easily put into an epileptic state by I. In thalamic pigeons application of I to the optic lobes followed by stimulation of reflexogenic cutaneous areas produced an epileptic state. Epilepsy could not be induced after the lobes were removed. Application of I to the

area

of the cerebral cortex controlling the mouth region of the rabbit

produced

epileptiform elec. responses measurable by elec. recordings. Epileptic reflexes of the Jacksonian type were also produced in the mouth region without any reflex cutaneous stimulation. In general, the action of I

was

similar to that of strychnine.

L28 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2001 ACS

TI **Neurotoxicity** of dihydrostreptomycin; effects of longer term therapy

AN 1952:21201 CAPLUS

DN 46:21201

OREF 46:3648i,3649a

TI **Neurotoxicity** of dihydrostreptomycin; effects of longer term

therapy  
AU O'Connor, John B.; Christie, Frederick J.; Howlett, Kirby S., Jr.  
SO Am. Rev. Tuberc. (1951), 63, 312-24  
DT Journal  
LA Unavailable  
AB The toxic effects of streptomycin (I) and of dihydrostreptomycin (II)  
were studied in 55 patients treated with one or the other of these drugs  
together with p-aminosalicylic acid concurrently. Toxic  
manifestations increased when patients were treated continuously for 6  
months or more with daily doses of 1.5 g. or less of I. The principal  
toxic manifestation with I was impairment of labyrinthine function and  
that with II was impairment of hearing.

=> ischemia

43217 ISCHEMIA  
49 ISCHEMIAS  
L33 43227 ISCHEMIA  
(ISCHEMIA OR ISCHEMIAS)

=> hypoxia

27300 HYPOXIA  
22 HYPOXIAS  
L34 27301 HYPOXIA  
(HYPOXIA OR HYPOXIAS)

=> neurotoxicity

12838 NEUROTOXICITY  
70 NEUROTOXICITIES  
L35 12859 NEUROTOXICITY  
(NEUROTOXICITY OR NEUROTOXICITIES)

=> oxidative stress

137690 OXIDATIVE  
17 OXIDATIVES  
137692 OXIDATIVE  
(OXIDATIVE OR OXIDATIVES)  
333577 STRESS  
68395 STRESSES  
362711 STRESS  
(STRESS OR STRESSES)  
L36 19016 OXIDATIVE STRESS  
(OXIDATIVE(W)STRESS)

=> l33 or l34 or l35 or l36

L37 95945 L33 OR L34 OR L35 OR L36

=> d his

(FILE 'HOME' ENTERED AT 13:02:17 ON 19 JUL 2001)

FILE 'REGISTRY' ENTERED AT 13:02:44 ON 19 JUL 2001

L1 STRUCTURE UPLOADED  
L2 0 SEARCH L1 EXACT FULL  
L3 149 SEARCH L1 SSS FULL  
L4 0 DSCAN

FILE 'CAPLUS' ENTERED AT 13:09:02 ON 19 JUL 2001



L5 40 L3  
L6 21548 EXCITATORY  
L7 155601 ANTAGONIST  
L8 6350 L6 AND L7  
L9 0 L5 AND L8  
L10 8515 NEURODEGEN?  
L11 0 L10 AND L5

FILE 'REGISTRY' ENTERED AT 13:19:06 ON 19 JUL 2001

L12 STRUCTURE UPLOADED  
L13 49 SEARCH L12 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:21:52 ON 19 JUL 2001

L14 17 L13  
L15 17393 NMDA  
L16 1 L15 AND L14  
L17 564689 ZN OR ZINC  
L18 14 L5 AND L14  
L19 13 L18 NOT L15  
L20 24156 TYROSINE KINASE  
L21 19386 ALZHEIMER?  
L22 105 L21 AND L20  
L23 147 L17 AND L20  
L24 1 L22 AND L23  
L25 119 L15 AND L20  
L26 4251 AMINOSALICYLIC  
L27 358651 NEURO?  
L28 26 L26 AND L27  
L29 12859 NEUROTOXICITY  
L30 2 L28 AND L29  
L31 25 HISTAMINERGIC AGONISTS  
L32 0 L21 AND L31  
L33 43227 ISCHEMIA  
L34 27301 HYPOXIA  
L35 12859 NEUROTOXICITY  
L36 19016 OXIDATIVE STRESS  
L37 95945 L33 OR L34 OR L35 OR L36

=> (l5 or l14) and l37

L38 0 (L5 OR L14) AND L37

=> l26 and l37

L39 20 L26 AND L37

=> d l39 1-10 ti

L39 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2001 ACS

TI 5-**aminosalicylic** acid protection against oxidative damage to synaptosomal membranes by alkoxyl radicals in vitro

L39 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2001 ACS

TI Synthesis, activity and formulations of pharmaceutical compounds for treatment of **oxidative stress** and/or endothelial dysfunction

L39 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2001 ACS

TI Hydroxyl radical adduct of 5-**aminosalicylic** acid: a potential marker of ozone-induced **oxidative stress**

L39 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI Synthesis, activity and formulations of pharmaceutical compounds for treatment of **oxidative stress** and/or endothelial dysfunction

L39 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI Synthesis, activity and formulations of pharmaceutical compounds for treatment of **oxidative stress** and/or endothelial dysfunction

L39 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI Bioreductive conjugates for drug targeting

L39 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes

L39 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier - implications for use of glucosamine in inflammatory disorders

L39 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI Implication of reactive oxygen metabolites in inflammatory bowel diseases

L39 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI Inhibition by aminosalicylates of lipid peroxidation in large intestinal mucosa after mesenteric **ischemia**/reperfusion in the rat

=> d 139 11-20 ti

L39 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI **Ischemia**/reperfusion injury in the rat colon

L39 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI **Ischemia** reperfusion damage in the gut and its treatment with drugs of the **aminosalicylic** acid group

L39 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI **Ischemia**/reperfusion injury in proximal colon and the therapeutic action of 5-ASA

L39 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI Effect of 5-**aminosalicylic** acid on myocardial capillary permeability following **ischemia** and reperfusion

L39 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI Peroxyl radical-mediated hemolysis: role of lipid, protein and sulfhydryl oxidation

L39 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI The antioxidative effect of sulfasalazine and mesalazine after intestinal **ischemia** and reperfusion

L39 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI Reduction potentials of antimycobacterial agents: relationship to

activity

L39 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2001 ACS  
TI 5-**Aminosalicylic** acid protects against **ischemia**  
/reperfusion-induced gastric bleeding in the rat

L39 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2001 ACS  
TI Studies on the melanin affinity of selegiline (deprenyl) and other  
amphetamine derivatives

L39 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2001 ACS  
TI **Neurotoxicity** of dihydrostreptomycin; effects of longer term  
therapy

=>

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	94.08	420.87
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-7.64	-7.64

FILE 'STNGUIDE' ENTERED AT 14:23:59 ON 19 JUL 2001  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jul 13, 2001 (20010713/UP).

=>

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.00	420.87
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-7.64

FILE 'CAPLUS' ENTERED AT 14:25:14 ON 19 JUL 2001  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 19 Jul 2001 VOL 135 ISS 4  
FILE LAST UPDATED: 18 Jul 2001 (20010718/ED)

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

This file supports REGISTRY for direct browsing and searching of

all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAPLUS now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=>

ANSWER SET L39 HAS BEEN SAVED AS 'BASINDICAT/A'

=> d l39 1,2,10,18,20 ti fbib abs

L39 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2001 ACS

TI 5-**aminosalicylic** acid protection against oxidative damage to synaptosomal membranes by alkoxyl radicals in vitro

AN 2001:348443 CAPLUS

TI 5-**aminosalicylic** acid protection against oxidative damage to synaptosomal membranes by alkoxyl radicals in vitro

AU Kanski, Jaroslaw; Lauderback, Christopher; Butterfield, D. Allan

CS Department of Chemistry, Center of Membrane Sciences, University of Kentucky, Lexington, KY, 40506, USA

SO Neurochem. Res. (2001), 26(1), 23-29

CODEN: NEREDZ; ISSN: 0364-3190

PB Kluwer Academic/Plenum Publishers

DT Journal

LA English

AB The antioxidant properties of 5-**aminosalicylic** acid in vitro were evaluated in a synaptosomal membrane system prep'd. from gerbil cortical synaptosomes using EPR spin labeling and spectroscopic techniques. MAL-6 (2,2,6,6-tetramethyl-4-maleimidopiperidin-1-oxyl) and 5-NS (5-nitroxide stearate) spin labels were used to assess changes in protein oxidn. and membrane lipid fluidity, resp. Synaptosomal membranes were subjected to **oxidative stress** by incubation with 1 mM azo-bis(isobutyronitrile) (AIBN) or 1 mM 2,2'-azobis(amidino propane)

dihydrochloride (AAPH) at 37.degree.C for 30 min. The EPR analyses of the

samples showed significant oxidn. of synaptosomal proteins and a decrease in membrane fluidity. 5-**Aminosalicylic** acid also was evaluated by means of FRAP (the ferric reducing ability of plasma) test as a potential antioxidant. 5-**Aminosalicylic** acid also showed protection against the oxidn. in gerbil cortical synaptosomes system caused by AIBN and AAPH. These results are consistent with the notion of antioxidant protection against free radical induced **oxidative stress** in synaptosomal membrane system by this agent.

RE.CNT 44

RE

(2) Aksenov, M; J Neurochem 2000, V74, P2520 CAPLUS

(3) Alho, H; Methods Enzymol 1999, V299, P3 CAPLUS

(4) Allgayer, H; Dig Dis Sci 1994, V39, P145 CAPLUS  
 (5) Aruoma, O; Biochem Pharmacol 1987, V36, P3739 CAPLUS  
 (6) Benzie, I; Anal Biochem 1996, V239, P70 CAPLUS  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L39 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI Synthesis, activity and formulations of pharmaceutical compounds for treatment of **oxidative stress** and/or endothelial dysfunction  
 AN 2001:137173 CAPLUS  
 DN 134:178396  
 TI Synthesis, activity and formulations of pharmaceutical compounds for treatment of **oxidative stress** and/or endothelial dysfunction  
 IN Del Soldato, Piero  
 PA Nicox S.A., Fr.  
 SO PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012584	A2	20010222	WO 2000-EP7225	20000727
	W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	IT 1999-MI1817 A 19990812				

OS MARPAT 134:178396  
 AB Compds. or their salts of general formula (I): A-B-N(O)s wherein: s is an integer equal to 1 or 2; A = R-T1-, wherein R is the drug radical and T1

=  
 (CO)t or (X)t', wherein X = O, S, NR1c, R1c is H or a linear or branched alkyl or a free valence, t and t' are integers and equal to zero or 1, with the proviso that t = 1 when t' = 0; t = 0 when t' = 1; B = -TB

-X2-O-  
 wherein TB = (CO) when t = 0, TB = X when t' = 0, X being as above defined; X2, bivalent radical, is such that the precursor drug of A and the precursor of B meet resp. the pharmacol. tests described in the description. Synthesis, activity and formulations of pharmaceutical compds. for treatment of **oxidative stress** and/or endothelial dysfunction are disclosed. The precursors are such as to

meet  
 the pharmacol. test reported in the description.

L39 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2001 ACS  
 TI Inhibition by aminosalicylates of lipid peroxidation in large intestinal mucosa after mesenteric **ischemia**/reperfusion in the rat  
 AN 1997:706586 CAPLUS  
 DN 128:18565  
 TI Inhibition by aminosalicylates of lipid peroxidation in large intestinal mucosa after mesenteric **ischemia**/reperfusion in the rat  
 AU Kumamoto, Takumi; Matsuda, Akihiko; Kataoka, Mikiko; Kokuba, Yukifumi  
 CS Research and Development Division, Development Laboratories, Nippon Hoechst Marion Roussel Ltd., Shiga, 520-23, Japan

SO Jpn. J. Pharmacol. (1997), 75(2), 187-189  
CODEN: JJPAAZ; ISSN: 0021-5198  
PB Japanese Pharmacological Society  
DT Journal  
LA English  
AB To clarify the mode of action of aminosalicylates, which are generally used as therapeutic agents for ulcerative colitis, we investigated the effect of some of the aminosalicylates on lipid peroxidn. in the large intestinal mucosa after mesenteric **ischemia**/reperfusion in the rat. Lipid peroxidn. was assessed by measuring the level of thiobarbituric-acid-reactive substances. It was found that aminosalicylates dose-dependently inhibited the elevation of the level of thiobarbituric-acid-reactive substances in the large intestinal mucosa after **ischemia**/reperfusion. This effect may partly contribute to the therapeutic actions of aminosalicylates in ulcerative colitis.

L39 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2001 ACS  
TI 5-**Aminosalicyclic** acid protects against **ischemia**  
/reperfusion-induced gastric bleeding in the rat  
AN 1988:124311 CAPLUS  
DN 108:124311  
TI 5-**Aminosalicyclic** acid protects against **ischemia**  
/reperfusion-induced gastric bleeding in the rat  
AU Kvietys, Peter R.; Smith, S. Morgan; Grisham, Matthew B.; Mancini, Elizabeth  
A.  
CS Coll. Med., Univ. South Alabama, Mobile, AL, USA  
SO Gastroenterology (1988), 94(3), 733-8  
CODEN: GASTAB; ISSN: 0016-5085  
DT Journal  
LA English  
AB **Ischemia**/reperfusion-induced gastric bleeding was shown in rats to involve the hydroxyl radical. 5-**Aminosalicyclic** acid (5-ASA) but not sulfapyridine attenuated the vascular injury. 5-ASA was effective when administered intragastrically at a concn. similar to that achieved clin. to manage diseases of the large bowel. Thus, this agent may be of clin. value in the treatment of gastric mucosal bleeding and ulcerations.

L39 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2001 ACS  
TI **Neurotoxicity** of dihydrostreptomycin; effects of longer term therapy  
AN 1952:21201 CAPLUS  
DN 46:21201  
OREF 46:3648i,3649a  
TI **Neurotoxicity** of dihydrostreptomycin; effects of longer term therapy  
AU O'Connor, John B.; Christie, Frederick J.; Howlett, Kirby S., Jr.  
SO Am. Rev. Tuberc. (1951), 63, 312-24  
DT Journal  
LA Unavailable  
AB The toxic effects of streptomycin (I) and of dihydrostreptomycin (II) were studied in 55 patients treated with one or the other of these drugs together with p-**aminosalicylic** acid concurrently. Toxic manifestations increased when patients were treated continuously for 6 months or more with daily doses of 1.5 g. or less of I. The principal toxic manifestation with I was impairment of labyrinthine function and that with II was impairment of hearing.

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

15.10

435.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.94

-10.58

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 14:33:18 ON 19 JUL 2001

Connecting via Winsock to STN

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal623paz

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files  
NEWS 3 Feb 06 Engineering Information Encompass files have new names  
NEWS 4 Feb 16 TOXLINE no longer being updated  
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure  
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA  
NEWS 7 May 07 DGENE Reload  
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL  
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's  
DWPI and DPCI

NEWS EXPRESS July 11 CURRENT WINDOWS VERSION IS V6.0b,  
CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2001

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*